Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention by Attanasio, Monica et al.
Thrombosis Research 147 (2016) 52–57
Contents lists available at ScienceDirect
Thrombosis Research
j ourna l homepage: www.e lsev ie r .com/ locate / th romresFull Length ArticleResidual thrombin potential predicts cardiovascular death in acute
coronary syndrome patients undergoing percutaneous
coronary interventionMonica Attanasio a,b,⁎, Rossella Marcucci a,b, Anna Maria Gori a,b,d, Rita Paniccia a,b, Serafina Valente b,
Daniela Balzi c, Alessandro Barchielli c, Nazario Carrabba b, Renato Valenti b, David Antoniucci b,
Rosanna Abbate d,e,f, Gian Franco Gensini d,e,f
a Department Experimental and Clinical Medicine, University of Florence, Italy
b Careggi University Hospital, Florence, Italy
c Epidemiology Unit, ASF Tuscany Region, Piero Palagi Hospital, Florence, Italy
d Don Gnocchi Foundation, Florence, Italy
e University of Florence, Italy
f CESMAV, Florence, Italy⁎ Corresponding author at: Department of Experim
University of Florence, Largo Brambilla 3, 50134 Florence,
E-mail address:monica.attanasio@unifi.it (M. Attanasi
http://dx.doi.org/10.1016/j.thromres.2016.09.020
0049-3848/© 2016 Published by Elsevier Ltd.a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 June 2016
Received in revised form 5 September 2016
Accepted 18 September 2016
Available online 19 September 2016Introduction: Thrombin generation (TG) is a central step of the coagulation system involved in hemostatic and
thrombotic roles. Scarce data evaluating in the acute phase the association between TG and the risk of cardiovas-
cular death of acute coronary syndrome (ACS) patients are available, in the era of percutaneous coronary inter-
vention (PCI) and stenting with the use of dual antiplatelet treatment.
Materials and methods:We investigated TG in 292 ACS patients undergoing PCI with stent implantation on dual
antiplatelet treatment. Venous samples were obtained 12–24 h after PCI. TG was assessed using the Calibrated
Automated Thrombogram (CAT).
Results: At two years of follow-up, 57 out of 292 patients (19.5%) died from cardiovascular causes. Higher values
of endogenous thrombin potential (ETP) [1115.9 (705–1441.3) vs 940.2 (666.0–1253.1), p= 0.049], peak [176.1
(80.5–259.4) vs 107.3 (59.9–181.1), p = 0.002] and velocity index [61.75 (21.03–97.88) vs 25.64 (11.95–50.90),
p b 0.001] were observed in relation to survival patients. At the multivariate model adjusted for the Global Reg-
istry of Acute Coronary Events risk score, the association between TG and cardiovascular death remained signif-
icant for ETP [OR (95% CI): 2.58 (1.10–6.03), p = 0.029], peak [OR (95%CI): 3.27 (1.35–7.92), p = 0.009] and
velocity index [OR (95% CI): 3.06 (1.27–7.39), p = 0.013]. This result was confirmed after adjustment for high
on-treatment platelet reactivity [ETP: OR (95% CI) 2.35 (1.11–5.00), p = 0.027; peak: OR (95% CI) 2.42 (1.13–
5.15), p = 0.022; velocity index: OR (95% CI) 2.43 (1.14–5.20), p = 0.022].
Conclusions: ACS patients with a residual TG after PCI and stent implantation have a significantly higher risk of
long-term cardiovascular death. These results might be useful in improving risk stratification for ACS patients
and support the need of a tailored antithrombotic therapy.
© 2016 Published by Elsevier Ltd.Keywords:
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Mortality1. Introduction
The most common underlying mechanism of acute coronary syn-
drome (ACS) is thrombus development on a damaged atherosclerotic
plaque. Thrombin is a serine proteinase and is involved in hemostatic
and thrombotic roles, frompromotion and inhibition of clotting, tofibri-
nolysis, platelet activation, and inflammation. In the past, biochemicalental and Clinical Medicine,
Italy.
o).signs of coagulation activation in the acute phase of unstable angina or
acute myocardial infarction (AMI) were demonstrated [1,2] and blood
clotting activation markers were found to be independent risk factors
for recurrence and long-term mortality [3–6]. In the last years the dif-
fuse use of PCI and stenting stimulated several studies investigating pri-
marily the role of platelet hyper-reactivity in determining clinical
outcome [7,8]. On the other hand, scarce data are available on the pos-
sible role of blood clotting activation on the prognosis of ACS patients,
in the era of PCI and stenting on the top of dual antiplatelet therapy.
In 2011 in a small group of AMI patients the risk of recurrent ischemic
cardiovascular complications was evaluated in relation to thrombin
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to obtain clear results [9]. In 2014 Schneider et al. investigated TG in a
non-homogeneous cohort of CAD patients (unstable and stable coro-
nary artery disease), performing the biohumoral evaluation in a large
time interval from the index event, found an inverse association be-
tween TG and cardiovascular death [10]. Aim of our study was to evalu-
ate the possible association between cardiovascular death and the
entity of thrombin generationmeasured in the acute phase of ACS in pa-
tients undergone PCI and stenting. We measured thrombin generation
(TG) by the CalibratedAutomated Thrombogram (CAT) assay, which of-
fers a global assessment of coagulation [11]. Residual platelet reactivity
was also evaluated in relation to the risk of cardiovascular death.
2. Methods
The study population comprised a group of 421 patients discharged
from the Coronary Unit of the Careggi University Hospital (Florence,
Italy) from April 2008 to April 2010 with a diagnosis of acute coronary
syndrome (ACS) and enrolled in the frame of the Florence Acute Myo-
cardial Infarction-2 (AMI-Florence 2) registry [12]. Fifty patients were
excluded as they interrupted dual antiplatelet therapy formajor surgery
(due to cardiovascular or liver disease or cancer) during the follow-up
in order to avoid the inclusion of ischemic events possibly occurring
for the therapy interruption. Sixty-six patients were lost at follow-up
and 13 patients were excluded as theywere on oral anticoagulant treat-
ment. Therefore, the final study population included 292 ACS patients
undergone PCI with stent implantation (155 ST-elevation myocardial
infarction [STEMI]; 137 NSTEMI/Unstable Angina). In all these patients
dual antiplatelet therapy was continued for 12 months. ACS was diag-
nosed according to criteria established by the European Society of Cardi-
ology [13]. Unstable anginawas defined as a history of new-onset, more
frequent, more persistent or rest episode of chest pain, without typical
changes of myocardial enzymes and with electrocardiogram evidence
of myocardial ischemia (transient ST segment displacement N 0.1 mV
during chest pain).
All patients underwent coronary angiography performed by the
Judkins' technique and percutaneous coronary intervention (PCI). Be-
fore PCI, all patients received a loading dose of 500 mg of acetylsalicylic
acid (ASA) and 600 mg of clopidogrel, followed by 100/325 mg of ASA
daily and 75 mg of clopidogrel daily. During PCI, standard activated
clotting time (ACT)-guided doses of intravenous unfractioned heparin
(UFH) were used (ACT: 250–300 s) after an 85 U/kg bolus of UFH.
Current smoking status was determined at the time of blood collec-
tion. The subjects were classified as having hypertension according to
the guidelines of European Society of Hypertension/European Society
of Cardiology [14] or if they reported taking antihypertensive medica-
tions, as verified by the physician. Diabetic subjects were defined in
agreement with the American Diabetes Association [15] or on the
basis of self-report data (if confirmed by medication or chart review).
Dyslipidemia was defined according to the Third report of the National
Cholesterol Education Program(NCEP-III) [16] or if they reported taking
antidyslipidemic drugs, as verified by the physician. A positive family
history was defined as the presence of at least one first-degree relative
who had developed coronary artery disease (CAD) before the age of
55 years for men and 65 years for women. All subjects gave informed
consent; the study complies with the Declaration of Helsinki and was
approved by the local ethic committee.
Venous blood samples anticoagulated with 0.109 M sodium citrate
were taken between 12 and 24 h after PCI. Platelet poor plasma for
the assessment of thrombin generation was obtained by double centri-
fugation at 2000 ×g for 15 min at room temperature and stored at−
80 °C until analysis.
As regard Calibrated Automated Thrombogram (CAT) assessment,
we used themethoddescribed byHemker and coworkers [17] and com-
mercialized by Thrombinoscope BV, (Maastricht, the Netherlands). Ac-
cording to the manufacturer's instructions, measurements wereconducted in 80 μl of platelet poor plasma (PPP) triggered by 20 μl
PPP-reagent (tissue factor 5 pmol/l) in 96-well microtiter plates. Mea-
surements were calibrated against the fluorescence curve obtained in
the same plasma mixed with 20 μl Thrombin Calibrator
(Thrombinoscope BV). Fluorogenic substrate (20 μl) were added to
sample and calibrator wells and the fluorescence intensity was detected
in a Fluoroskan Ascent reader (Thermo Labsystems OY, Helsinki, Fin-
land) with a 390/460 filter set for 60min and the TG curves were calcu-
lated with Thrombinoscope software (Thrombinoscope BV). TG was
expressed as endogenous thrombin potential (ETP: the area under the
curve that represents the total amount of thrombin generated), peak
(the maximum concentration of thrombin produced), and velocity
index (the slope between the start of thrombin formation and the
peak). To rule out any “contamination” of unfractioned heparin (UFH),
anti-Xa levels were determined in all samples. Only sampleswith unde-
tectable anti-Xa (b0.05 U ml) were considered to be free of UFH and
only these samples were included in the analysis.
To assess platelet reactivity, platelet-rich plasma, obtained by
centrifuging whole blood for 10 min at 200g, was stimulated with
10 μM adenosine diphosphate (ADP; Mascia Brunelli, Milan, Italy), and
with 1 mM arachidonic acid (AA; Sigma-Aldrich, Milan, Italy) and ag-
gregation was assessed using a APACT 4 light transmission
aggregometer (Helena Laboratories, Milan, Italy) as previously reported
[18].We defined patients with high platelet reactivity (HPR) those with
platelet aggregation by AA ≥20% and/or by ADP ≥70% [19–22].
All datawere prospectively collected and entered into a central data-
base. Clinical follow-up information was obtained by contacting all the
patients. All possible information derived also from hospital readmis-
sion or by referring physician, relatives, or municipality live registries
were entered into the prospective database. All deaths were considered
cardiac unless an unequivocal non cardiac cause could be documented.
Statistical analysiswasperformed using the SPSS (Statistical Package
for Social Sciences, Chicago, IL, USA) software for Windows (Version
21.0). Values are presented as median and interquartile range (IQR).
The Mann-Whitney test for unpaired data was used for comparison be-
tween two groups. Dichotomous variables were compared by Chi2 test.
A receiver operating characteristic curve (ROC) analysis was used to de-
termine the ability of TG parameters in predicting cardiovascular death
at 24 months. The optimal cut-off point was calculated by determining
the TG parameters that provided the greatest sum of sensitivity and
specificity. We defined patients with residual TG those with ETP ≥
1027.2 nM/min and/or peak ≥ 139.28 nM and/or velocity index ≥ 35.7
nmol/min. Cumulative survival curves were constructed by the Kaplan
Meiermethod, and the log-rank test was used to assess statistical differ-
ences between survival curves. In order to test the independent associ-
ation between TGparameters and cardiovascular death,we performed a
multiple logistic regression analysis adjusted for an established risk
score which has been extensively validated such as the Global Registry
of Acute Coronary Events (GRACE) risk score (which includes age,
heart rate, systolic blood pressure, creatinine, Killip class, elevated cardi-
ac enzymes, ST-segment deviation, cardiac arrest at admission). All odds
ratios (OR) are given with their 95% confidence interval (CI). p b 0.05
was considered to be statistically significant.3. Results
We investigated thrombin generation in 292 (217 men/75 women)
ACS patients (155 ST-elevation myocardial infarction [STEMI]; 137
NSTEMI/Unstable Angina).
TG parameters did not significantly differ in relation to age, sex,
smoking habit, hypertension, dyslipidemia, diabetes and leukocyte
number (data not shown). Higher values of peak (192.21; IQR 141.73–
249.35) and velocity index (59.58; IQR 42.22–100.89) were found in
ACS patients with renal failure respect to those without renal failure
[peak 119.33 (IQR 61.21–200.42); velocity index 30.62 (IQR 12.62–
Table 1
Clinical characteristics of patients investigated.
Overall group
n = 294 (%)
CV death
n = 57 (%)
No CV death
n = 237 (%)
pb
Age, yearsc 76 (65–84) 86 (80–90) 72 (62–81) 0.000
Male gender, n (%) 218 (74.1) 33 (57.9) 185 (78.1) 0.0037
Diabetes, n (%) 80 (27.2) 20 (35.1) 60 (25.3) NS
Smoking habit, n (%) 181 (61.6) 29 (50.1) 152 (64.1) 0.0703
Hypertension, n (%) 185 (62.9) 38 (66.7) 147 (62.0) NS
Dyslipidemia, n (%) 119 (40.5) 21 (36.8) 98 (41.4) NS
Renal failurea, n (%) 14 (4.8) 8 (14.0) 6 (2.5) 0.0015
STEMI, n (%) 157 (53.4) 24 (42.1) 133 (56.1) NS
ACE-inhibitors, n (%) 70 (23.8) 21 (36.8) 49 (20.1) NS
Ca-antagonists, n (%) 62 (21.1) 16 (28.1) 46 (19.4) NS
Beta-blockers, n (%) 70 (23.8) 21 (36.8) 49 (20.1) 0.0147
Antiarrhythmic, n (%) 17 (5.8) 4(7.0) 13 (5.5) NS
Statins, n (%) 76 (25.9) 16 (28.1) 60 (25.3) NS
Nitrates, n (%) 44 (15.0) 14 (24.6) 30 (12.7) 0.0366
AntiIIbIIIa 6 (2.0) 1 (1.8) 5 (2.1) NS
Killip class 1 195 (66.3) 33 (57.9) 162 (68.4) 0.000
Killip class N1 53 (18.0) 24 (42.1) 21 (8.9)
One vessel treated, n (%) 94 (32.0) 15 (26.3) 79 (33.3) NS
Two vessel treated, n (%) 103 (35.0) 20 (35.1) 83 (35.0)
Three vessel treated, n (%) 97 (33.0) 22 (38.6) 75 (31.6)
CV: cardiovascular death.
a Renal insufficiency defined by creatinine levels above 2.0 mg/dl.
b CV death vs no CV death.
c Values are expressed as median and (range).
54 M. Attanasio et al. / Thrombosis Research 147 (2016) 52–5766.40)] (p b 0.005). No significant differences in TG values according to
Killip class and STEMI /NSTEMI were found (data not shown).
At two-year follow-up, 57 out of 292 patients (19.5%) died from car-
diovascular causes. Cardiac mortality rate was 11.2% (n = 33) at 6
months and 9.2% (n = 24) at 6–24 months. With regards to cardiovas-
cular risk factors, patients who died during the follow-up were signifi-
cantly older, with a higher prevalence of females and renal failure, and
with a higher Killip class as compared to patients who remained alive
(Table 1).
Among hematological parameters, patients who died during follow-
up showed significant lower values of hemoglobin, hematocrit, red
blood cells and a significantly higher number of leukocytes (Table 2).
Higher values of ETP, peak and velocity index were detected in dead
compared to alive patients (Table 2).
The landmark analysis using the prespecified starting point of 6
months showed that the differences between groups according to cardi-
ac mortality emerged in the short-term follow-up as well as from 6
months to long term.
Receiver operating characteristics (ROC) curve analyses (Fig. 1)
identified ETP = 1027.2 nMxmin, peak = 139.28 nM, and velocity
index = 35.7 nmol/min as the optimal cut-off values to predict cardio-
vascular death [ETP area under curve 58% (50–67), p=0.029; peak areaTable 2
Laboratory parameters of patients investigated.
Overall group
(n = 294)
CV
(n
ETP (nM/min) 986 (665–1269) 11
Peak (nM) 117 (61–193) 17
Velocity index (nM/min) 30 (13–63) 62
Leukocytes (×103/μl) 9645 (7325–12,575) 11
Red blood cells (×106/μl) 4.64 (4.24–4.99) 4.3
Hemoglobin (g/dl) 14.0 (12.5–15.0) 12
Hematocrit (%) 41.4 (36.9–44.5) 37
Platelets (×103/μl) 225 (191–268) 23
Creatinine (mg/dl) 0.93 (0.76–1.11) 1.1
CK-MB (ng/ml) 67.7 (18.8–176.8) 43
AA and/or ADP-HRPR, n (%) 99 (33.7) 29
Values are expressed as median and interquartile range. CV: cardiovascular death; ETP: endog
with platelet aggregation by AA ≥20% and/or by ADP ≥70%; CK-MB: Creatine Kinase MB.
a CV death vs no CV death.under the curve 63% (54–72), p = 0.002; velocity index area under the
curve 65% (56–74), p b 0.001].
By using these cut-off values, significantly higher percentages of pa-
tients with ETP ≥ 1027.2 nM/min, peak ≥ 139.28 nM, and velocity
index ≥ 35.7 nmol/minwere observed among thosewhodied compared
to those patients who remained alive [ETP: 33 (57.9%) vs 100 (42.2%),
p = 0.039; peak: 35 (61.4%) vs 92 (38.8%), p = 0.003; velocity index:
36 (63.2%) vs 90 (37.9%), p = 0.001].
Kaplan Meier curves for cardiovascular death according to higher
ETP, peak, and velocity index significantly diverged (Fig. 2).
In order to evaluate the association of thrombin generationwith the
occurrence of cardiovascular death we performed a logistic regression
analysis. In the univariatemodel ETP, peak, and velocity index, together
with age, female sex, leukocyte number, renal failure and Killip class,
were significantly associated with the risk of cardiovascular death
(Table 3). At the multivariate analysis, adjusted for the traditional car-
diovascular risk factors (age, male gender, smoking, hypertension, dys-
lipidemia, diabetes mellitus) and for the Global Registry of Acute
Coronary Events (GRACE) risk score variables, ETP, peak, velocity
index, leukocyte number, and age remained significantly associated
with the risk of cardiovascular death (Table 3).
In our population, the prevalence of HPR by ADP and/or by AA was
33.9% (n = 99). Cardiovascular mortality rate was 29.3% (29/99) in
the HPR by ADP and/or by AA and 14.5% (28/193) in the low residual
platelet reactivity group (p = 0.004). At univariate logistic regression
analysis high residual platelet reactivity was a significant predictor of
mortality [OR: 2.31 (95% CI 1.28–4.18), p = 0.006]. After adjustment
for the traditional cardiovascular risk factors and for the Global Registry
of Acute Coronary Events (GRACE) risk score variables, HPR remained
independently associated with mortality [OR 2.09; 95% CI 1.07–4.07),
p = 0.031].
At amultivariate logistic regression analysis in a full model including
HPR, thrombin generation variables and the other independent vari-
ables, HPR, ETP ≥ 1027.2 nM/min, peak ≥ 139.28 nM, and velocity
index ≥ 35.7 nmol/min, remained significantly and independently asso-
ciated with cardiovascular mortality (HPR: OR 2.51 (95% CI 1.17–5.40),
p = 0.018; ETP: OR 2.35 (95% CI 1.11–5.00), p = 0.027; peak: OR 2.42
(95% CI 1.13–5.15), p = 0.022; velocity index: OR 2.43 (95% CI 1.14–
5.20), p = 0.022].4. Discussion
In the present study we have found that: 1) the entity of thrombin
generation after PCI with stent implantation is an independent predic-
tor of cardiovascular death in ACS patients; 2) the risk of cardiovascular
death associated with thrombin generation is independent of platelet
reactivity.death
= 57)
No CV death
(n = 237)
pa
16 (701–1441) 940 (664–1260) 0.048
6 (81–259) 107 (60–181) 0.002
(21–98) 26 (12–50) 0.000
,350 (8608–14,675) 9220 (6975–12,100) 0.004
9 (3.72–4.76) 4.72 (4.39–5.03) 0.001
.7 (11.2–13.9) 14.1 (13.0–15.2) 0.000
.6 (33.4–41.8) 42.3 (38.7–44.9) 0.000
3 (197–264) 222 (189–270) NS
0 (0.86–1.70) 0.90 (0.74–1.06) 0.000
.00 (19.6–185.6) 75.95 (15.5–175.4) NS
(50.9) 70 (29.5) 0.002
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Fig. 1. Receiver-operating characteristic curves for: endogenous thrombin potential (ETP) (1), peak (2) and velocity index (3).
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of cardiovascular death at multivariate analysis were advanced age,
and Killip class N 1. As regards laboratory parameters, white blood cell
count (N10,000 cells/μl) was significantly higher in patients with unfa-
vorable prognosis and independent predictor of death at multivariate
analysis. This confirms that the exaggerate inflammatory response oc-
curring in these patients contributes to the worse prognosis [23,24].
As regards thrombin generation, ETP, peak thrombin and velocity
index were significantly higher in patients who died compared to
alive patients during 24-month follow-up. At multivariate analysis
ETP, peak thrombin and velocity index remained significantly associat-
ed with cardiovascular death.A) ETP
B) Peak
Fig. 2. Kaplan-Meier curves for cardiovascular death according to elevated values oIt is well known that blood clotting activation,mostly evaluating sin-
gle markers such as fibrinopeptide A, prothrombin fragment 1 + 2 and
D-dimer, is present in ACS patients and it is associatedwith unfavorable
outcomes [25,4,26]. Themajority of these evidences derived from stud-
ies conducted when invasive procedures and stent implantation were
less extensively performed. In the era of PCI and stenting with dual an-
tiplatelet therapy, two papers evaluated thrombin generation in CAD
patients. In 2011 Smid and coworkers [9] in a small group of AMI pa-
tients obtained no conclusive results of the role of hypercoagulability
in determining the risk of recurrent ischemic cardiovascular complica-
tions due to the low percentage of clinical events. In 2014 the LURIC
study observed in a large, but non homogeneous cohort of CAD patientsC) Velocity index
f endogenous thrombin potential (ETP) (A), peak (B) and velocity index (C).
Table 3
Predictors of cardiovascular death.
Univariate analyses Multivariate analyses
OR (95% CI) p OR (95% CI) p
ETP ≥ 1027.2 nMxmin 1.86 1.03–3.34 0.039 2.58 1.10–6.03 0.029
Peak ≥ 139.28 nM 2.47 1.37–4.48 0.003 3.27 1.35–7.92 0.009
Velocity index ≥ 35.7
nM/min
2.76 1.52–5.03 0.001 3.06 1.27–7.39 0.013
Age (years) 1.15 1.10–1.20 0.000 1.17 1.10–1.23 b0.001
Sex, female 2.62 1.43–4.83 0.002 0.92 0.39–2.20 0.857
Renal failure 7.63 2.21–26.40 0.001 6.49 0.61–18.67 0.120
Killip class 1.45 1.10–1.92 0.010 1.54 0.99–2.39 0.055
Leukocyte number 1.13 1.05–1.22 0.002 1.21 0.9–1.35 b0.001
CI: confidence interval; ETP: endogenous thrombin potential; OR: odd ratio.
56 M. Attanasio et al. / Thrombosis Research 147 (2016) 52–57(unstable and stable coronary disease) an inverse association between
cardiovascular death and ETP, investigated within the first month
from the index event [10].
Ourfindingsmay appear discordant from these resultswhich under-
pin the thrombin-paradox. Nevertheless, clinical setting and timing of
the evaluation were not comparable with our study. In our setting we
explored thrombin generation in ACS patients within 24 h from
clopidogrel loading and periprocedural heparin administration in
patients undergoing PCI with stent implantation. Furthermore our
patients were older, with higher prevalence of traditional cardiovascu-
lar risk factors and with a higher cardiovascular risk, as shown by the
different incidence of mortality.
We found that, despite an optimal antithrombotic therapy and a
periprocedural anticoagulant treatment, in a subset of patients (43%) a
residual thrombin generation is yet detectable after PCI. It is known
that ACS is associatedwith a hypercoagulability state and for this reason
it is essential to use anticoagulant treatment in the management of
these patients. Nevertheless, we have demonstrated that, on the top of
antithrombotic treatment performed according to guidelines, in some
patients a residual thrombin generation is detectable after PCI. These
patients have a significantly higher risk of long-term cardiovascular
death.
On the other hand, a large body of evidence has documented the as-
sociation between the entity of platelet reactivity on treatment and the
risk of cardiac death, stent thrombosis and ischemic recurrences. In this
study we have confirmed this datum. Additionally, our results suggest
that both residual thrombin generation and platelet reactivity are asso-
ciated – but independently –with cardiovascular death. From a clinical
point of view, these results are supporting the presence of patients in
which it might be more relevant to obtain an adequate platelet or
clotting inhibition.
Thrombin is one of themore potent platelet activators and hyper-re-
active platelets affect clotting system. Results obtained at multivariate
analysis indicate that thrombin generation and platelet reactivity are
two distinct phenomena affecting independently cardiovascular out-
come. However, in this study patients were on dual antiplatelet therapy
with aspirin and clopidogrel; so, we cannot exclude variations on these
results in the presence of the new and more potent antiplatelet drugs.
Limitations of our study are that we measured TG at one time only,
that we observed as endpoint the cardiovascular death only, and that
we did not measure markers of thrombin generation, nor other
proteins, known to be positive determinants of thrombin generation.
Another limitation of the study is that we did not analyzed
thrombophilic polymorphisms.
Our study adds new evidence that thrombin generation parameters
could be useful biomarkers for ACS risk stratification immediately after
PCI. The measurement of thrombin generation might help clinicians to
detect ACS patients at higher risk of adverse event during the follow-
up, who could obtain advantage by a prolonged antithrombotic
treatment.Disclosures
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